Clonal hematopoiesis and its emerging effects on cellular therapies
Open Access
- 2 July 2021
- journal article
- review article
- Published by Springer Science and Business Media LLC in Leukemia
- Vol. 35 (10), 2752-2758
- https://doi.org/10.1038/s41375-021-01337-8
Abstract
The accumulation of somatic mutations in hematopoietic stem cells during aging, leading to clonal expansion, is linked to a higher risk of cardiovascular mortality and hematologic malignancies. Clinically, clonal hematopoiesis is associated with a pro-inflammatory phenotype of hematopoietic cells and their progeny, inflammatory conditions and a poor outcome for patients with hematologic neoplasms and solid tumors. Here, we review the relevance and complications of clonal hematopoiesis for the treatment of hematologic malignancies with cell therapeutic approaches. In autologous and allogeneic hematopoietic stem cell transplantation native hematopoietic and immune effector cells of clonal origin are transferred, which may affect outcome of the procedure. In chimeric antigen receptor modified T-cell therapy, the effectiveness may be altered by preexisting somatic mutations in genetically modified effector cells or by unmodified bystander cells harboring clonal hematopoiesis. Registry studies and carefully designed prospective trials will be required to assess the relative roles of donor- and recipient-derived individual clonal events for autologous and allogeneic cell therapies and to incorporate novel insights into therapeutic strategies.Keywords
This publication has 99 references indexed in Scilit:
- Detectable clonal mosaicism from birth to old age and its relationship to cancerNature Genetics, 2012
- Detectable clonal mosaicism and its relationship to aging and cancerNature Genetics, 2012
- TET2 is essential for survival and hematopoietic stem cell homeostasisLeukemia, 2012
- Dnmt3a is essential for hematopoietic stem cell differentiationNature Genetics, 2011
- Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in miceProceedings of the National Academy of Sciences of the United States of America, 2011
- Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid TransformationCancer Cell, 2011
- TET2 Inactivation Results in Pleiotropic Hematopoietic Abnormalities in Mouse and Is a Recurrent Event during Human LymphomagenesisCancer Cell, 2011
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Mutation inTET2in Myeloid CancersThe New England Journal of Medicine, 2009
- Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia veraBlood, 2006